Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.

By WebmasterApril 2, 2020November 1st, 2024No Comments

Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.

Previous PostHalo Labs Raises $12M in Series B1 Financing Round and Enters into the FDA Market
Next PostRelmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety